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Clinics 
Age and sex: 61 years old female patient. 
Previous history: no preleukemia; no inborn condition 
of note; Breast cancer diagnosed in 2002, treated with 
radical mastectomy, chemotherapy with 
cyclophosphamide, epirubicin, 5-fluoro-uracil, 
radiotherapy. 
Organomegaly: no hepatomegaly; no splenomegaly; no 
enlarged lymph nodes; no central nervous system 
involvement. 
Blood 
WBC: 2.4 x 109/l; Hb: 10.7 g/dl; platelets: 48x 109/l; 
blasts: 2% 
Bone marrow: Neutrophils 0.05%; Band cells 0.05%; 
Metamyelocytes 0.13%; Myelocytes 0.02%; 
Promyelocytes 0.02%; Blasts 0.51%; Late normoblasts 
0.13%; Plasma cells 0.01%; Lymphocytes 0.05%; 
Monocytes 0.01%; Eosinophils 0.02%. 
Cytopathology classification 
Cytology: AML-M2. 
Immunophenotype: Positive for HLA-DR, CD34, 
CD117, CD13, CD33, MPO, CD56 and CD19; Partial 
Tdt; Negative for CD7. 
Precise diagnosis: Hypoplastic AML, therapy related. 
Survival 
Date of diagnosis: 04-2005. 
Treatment: Three cycles of AraC and Danuribicin; 
related bone marrow transplantation planned for 
September 2005. 
 
Complete remission: Yes, 05-2005 
Status: Alive (07-2005) 
Survival: 3 months 
Karyotype 





Partial karyotype showing the t(16;21) and a +8 
Comments 
The t(16;21)(q24;q22) is mainly found in t- MDS /t-
AML (14/16 cases (1-10)), following breast cancer 
therapy (five cases (7,8,10)), lymphoma (four cases), 
Hodgkin's disease, lung and oviductal cancers and 
AML-M3 (one case each). Trisomy 8, the secondary 
change found in the current case, is also reported in 
most if not all patients with previous breast cancer 
(7,8,10). 
To note, three out of five patients had lymphoid 
positive antigenes (5,7, current case). 
All of the nine patients whose treatments were repot d 
(3-9), plus the current case, were treated with a 
combination of alkylating agents and topoisomerase II 
inhibitors, +/- radiotherapy. 
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